-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Maintains Buy on Nuvectis Pharma, Raises Price Target to $33

Benzinga·07/06/2026 09:18:17
Listen to the news
Roth Capital analyst Jonathan Aschoff maintains Nuvectis Pharma (NASDAQ:NVCT) with a Buy and raises the price target from $20 to $33.